Patient-Centric Approaches to Managing Migraines in the Female Patient

Patient-Centric Approaches to Managing Migraines in the Female Patient

ReachMD Healthcare Image
RestartResume

Migraine can have a substantial negative impact on a woman’s quality of life, yet diagnosis and treatment are often delayed. See how we can do better!

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Jessica Ailani, MD
    Director, Georgetown Headache Center
    MedStar Georgetown University Hospital
    Washington, DC

    Dr. Ailani has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Ipsen, Parema, Satsuma
    Consulting Fees: AbbVie, Aeon, Amgen, Axsome, Biohaven, GlaxoSmithKline, Gore, Impel, Ipsen, Lilly, Lundbeck, Merz, Miravo, Neurolief, Pfizer, Satsuma, Teva, Theranica

    Faculty:
    Dawn C. Buse, PhD
    Clinical Professor
    Albert Einstein College of Medicine
    Bronx, NY

    Dr. Buse has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Allergan/AbbVie, Amgen, Biohaven, Collegium, Lilly, Lundbeck, Teva, Theranica

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Samantha Keehn has nothing to disclose.
    • Brian McDonough, MD, has nothing to disclose.
    • Tim Person has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the unique impact of migraine on a woman’s quality of life 
    • Explain the pathophysiologic role of calcitonin gene-related peptide (CGRP) in migraine 
    • Discuss data supporting use of CGRP pathway modulation in the management of migraine 
  • Target Audience

    This activity is designed to meet the educational needs of ob-gyns, nurse practitioners, physician associates, nurses, and pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 02/13/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.025 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is UAN JA0006235-0000-24-024-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)


    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie Inc. and Pfizer Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free